Savient's New CEO Johnson Tasked With Turning Krystexxa Into A Commercial Success
This article was originally published in The Pink Sheet Daily
Executive Summary
Eli Lilly's oncology head John Johnson has been named to the top post at Savient Pharmaceuticals as the company tries to rebound from a failed sales attempt.
You may also be interested in...
Private Equity-Backed Crealta Makes Its First Move With Savient Deal
A startup called Crealta Pharmaceuticals will acquire most of Savient’s assets, including the marketed gout drug Krystexxa, for $120.4 million following a bankruptcy court auction.
Krystexxa Cleared For Refractory Gout, Could Reach Patients By Year's End
Despite black box warning for anaphylaxis and infusion reactions, label and risk plan are seen as "benign" by analysts.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.